GSK-3β activity and hyperdopamine-dependent behaviors

Neuroscience and Biobehavioral Reviews

Volumn 35, Issue 3, 2011, Pages 645-654

  Li, Yan Chun ^a   Gao, Wen Jun ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Akt; GPCR; GSK 3 ; Hyperdopamine; Psychiatric disorders; Signal transduction

Indexed keywords

AMPA RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ARRESTIN; CALCIUM ION; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE; DOPAMINE 2 RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOPROTEIN DARPP 32; PROTEIN KINASE B; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BEHAVIOR; BIPOLAR DISORDER; BRAIN FUNCTION; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DRUG MECHANISM; ENZYME ACTIVITY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NERVOUS SYSTEM DISEASES; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION;

EID: 78649908226     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2010.08.001     Document Type: Review

References (169)

1. Abi-Dargham A., Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003, 9:404-416.
2. Alimohamad H., Rajakumar N., Seah Y.-H., Rushlow W. Antipsychotics alter the protein expression levels of [beta]-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiatry 2005, 57:533-542.
3. Alimohamad H., Sutton L., Mouyal J., Rajakumar N., Rushlow W.J. The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J. Neurochem. 2005, 95:513-525.
4. Amar S., Shaltiel G., Mann L., Shamir A., Dean B., Scarr E., Bersudsky Y., Belmaker R.H., Agam G. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int. J. Neuropsychopharmacol. 2008, 11:197-205.
5. Andersen S.L. Changes in the second messenger cyclic AMP during development may underlie motoric symptoms in attention deficit/hyperactivity disorder (ADHD). Behav. Brain Res. 2002, 130:197-201.
6. Arguello P.A., Gogos J.A. A signaling pathway AKTing up in schizophrenia. J. Clin. Invest. 2008, 118:2018-2021.
7. Arnsten A.F., Goldman-Rakic P.S. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch. Gen. Psychiatry 1998, 55:362-368.
8. Arnsten A.F. Stress impairs prefrontal cortical function in rats and monkeys: role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms. Prog. Brain Res. 2000, 126:183-192.
9. Arnsten A.F.T. Stress signalling pathways that impair prefrontal cortex structure and function. Nat. Rev. Neurosci. 2009, 10:410-422.
10. Artigas F. The prefrontal cortex: a target for antipsychotic drugs. Acta Psychiatr. Scand. 2010, 121:11-21.
11. Balaraman Y., Limaye A.R., Levey A.I., Srinivasan S. Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. Cell. Mol. Life Sci. 2006, 63:1226-1235.
12. Beaulieu J.-M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007, 28:166-172.
13. Beaulieu J.-M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., Borrelli E., Caron M.G. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J. Neurosci. 2007, 27:881-885.
14. Beaulieu J.-M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49:327-347.
15. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5099-5104.
16. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
17. Beaulieu J.M., Sotnikova T.D., Gainetdinov R.R., Caron M.G. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J. Biol. Chem. 2006, 281:32072-32080.
18. Beaulieu J.M., Zhang X., Rodriguiz R.M., Sotnikova T.D., Cools M.J., Wetsel W.C., Gainetdinov R.R., Caron M.G. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:1333-1338.
19. Bersudsky Y., Shaldubina A., Kozlovsky N., Woodgett J.R., Agam G., Belmaker R.H. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav. Pharmacol. 2008, 19:217-224.
20. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., Lee C.M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11074-11079.
21. Bjorklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30:194-202.
22. Bychkov E., Ahmed M.R., Dalby K.N., Gurevich E.V. Dopamine depletion and subsequent treatment with l-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J. Neurochem. 2007, 102:699-711.
23. Cagniard B., Balsam P.D., Brunner D., Zhuang X. Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 2006, 31:1362-1370.
24. Cagniard B., Beeler J.A., Britt J.P., McGehee D.S., Marinelli M., Zhuang X. Dopamine scales performance in the absence of new learning. Neuron 2006, 51:541-547.
25. Cannon C.M., Palmiter R.D. Reward without dopamine. J. Neurosci. 2003, 23:10827-10831.
26. Cannon C.M., Bseikri M.R. Is dopamine required for natural reward?. Physiol. Behav. 2004, 81:741-748.
27. Carelli R.M. Nucleus accumbens cell firing and rapid dopamine signaling during goal-directed behaviors in rats. Neuropharmacology 2004, 47(Suppl. 1):180-189.
28. Carlson C.D., Cavazzoni P.A., Berg P.H., Wei H., Beasley C.M., Kane J.M. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J. Clin. Psychiatry 2003, 64:898-906.
29. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 2001, 41:237-260.
30. Castner S.A., Williams G.V. From vice to virtue: insights from sensitization in the nonhuman primate. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31:1572-1592.
31. Chen J.C., Chen P.C., Chiang Y.C. Molecular mechanisms of psychostimulant addiction. Chang Gung Med. J. 2009, 32:148-154.
32. Chen P., Gu Z., Liu W., Yan Z. Glycogen synthase knase 3 regulates NMDA receptor channel trafficking and function in cortical neurons. Mol. Pharmacol. 2007, 72:40-51.
33. Chen P., Lao C., Chen J. Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization. J. Neurochem. 2007, 100:225-241.
34. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell. Biol. 2001, 2:769-776.
35. Cohen P., Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 2004, 3:479-487.
36. Conn P.J., Tamminga C., Schoepp D.D., Lindsley C. Schizophrenia: moving beyond monoamine antagonists. Mol. Interv. 2008, 8:99-107.
37. Cyr M., Beaulieu J.M., Laakso A., Sotnikova T.D., Yao W.D., Bohn L.M., Gainetdinov R.R., Caron M.G. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11035-11040.
38. Darvas M., Palmiter R.D. Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14664-14669.
39. Darvas M., Palmiter R.D. Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition. J. Neurosci. 2010, 30:1158-1165.
40. Del'guidice T., Beaulieu J.-M. Messing up with traffic: gifferent effects of antipsychotic agents on glutamate receptor complexes in vivo. Mol. Pharmacol. 2008, 73:1339-1342.
41. Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav. Brain Res. 2002, 137:75-114.
42. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116:1175-1186.
43. Dzirasa K., Ramsey A.J., Takahashi D.Y., Stapleton J., Potes J.M., Williams J.K., Gainetdinov R.R., Sameshima K., Caron M.G., Nicolelis M.A. Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling. J. Neurosci. 2009, 29:8215-8224.
44. Dzirasa K., Santos L.M., Ribeiro S., Stapleton J., Gainetdinov R.R., Caron M.G., Nicolelis M.A. Persistent hyperdopaminergia decreases the peak frequency of hippocampal theta oscillations during quiet waking and REM sleep. PLoS One 2009, 4:e5238.
45. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 2002, 8:126-132.
46. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004, 36:131-137.
47. Esteban J.A., Shi S.H., Wilson C., Nuriya M., Huganir R.L., Malinow R. PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat. Neurosci. 2003, 6:136-143.
48. Fang X., Yu S.X., Lu Y., Bast R.C., Woodgett J.R., Mills G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11960-11965.
49. Farber N.B., Newcomer J.W., Olney J.W. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog. Brain Res. 1998, 116:421-437.
50. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31:1556-1571.
51. Forde J.E., Dale T.C. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell. Mol. Life Sci. 2007, 64:1930-1944.
52. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 2001, 359:1-16.
53. Freyberg Z., Ferrando S.J., Javitch J.A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am. J. Psychiatry 2009.
54. Gainetdinov R.R., Jones S.R., Caron M.G. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry 1999, 46:303-311.
55. Gainetdinov R.R., Mohn A.R., Bohn L.M., Caron M.G. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:11047-11054.
56. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001, 24:527-533.
57. Gainetdinov R.R., Caron M.G. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 2003, 43:261-284.
58. Gainetdinov R.R., Premont R.T., Bohn L.M., Lefkowitz R.J., Caron M.G. Desensitization of g protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 2004, 27:107-144.
59. Gao W.J., Krimer L.S., Goldman-Rakic P.S. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:295-300.
60. George S.R., O'Dowd B.F. A novel dopamine receptor signaling unit in brain: heterooligomers of D1 and D2 dopamine receptors. Scientific World J. 2007, 7:58-63.
61. Goto Y., Grace A.A. Alterations in medial prefrontal cortical activity and plasticity in rats with disruption of cortical development. Biol. Psychiatry 2006, 60:1259-1267.
62. Goto Y., Otani S., Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 2007, 53:583-587.
63. Gould T.D., Einat H., Bhat R., Manji H.K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 2004, 7:387-390.
64. Gould T.D., Picchini A.M., Einat H., Manji H.K. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets 2006, 7:1399-1409.
65. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294:1024-1030.
66. Gresch P.J., Sved A.F., Zigmond M.J., Finlay J.M. Stress-induced sensitization of dopamine and norepinephrine efflux in medial prefrontal cortex of the rat. J. Neurochem. 1994, 63:575-583.
67. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65:391-426.
68. Gurevich E.V., Gurevich V.V. Arrestins: ubiquitous regulators of cellular signaling pathways. Genome Biol. 2006, 7:236.
69. Gurevich V.V., Gurevich E.V. How and why do GPCRs dimerize?. Trends Pharmacol. Sci. 2008, 29:234-240.
70. Harwood A.J. Neurodevelopment and mood stabilizers. Curr. Mol. Med. 2003, 3:472-482.
71. Hironaka N., Ikeda K., Sora I., Uhl G.R., Niki H. Food-reinforced operant behavior in dopamine transporter knockout mice: enhanced resistance to extinction. Ann. N. Y. Acad. Sci. 2004, 1025:140-145.
72. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406:86-90.
73. Hooper C., Markevich V., Plattner F., Killick R., Schofield E., Engel T., Hernandez F., Anderton B., Rosenblum K., Bliss T., Cooke S.F., Avila J., Lucas J.J., Giese K.P., Stephenson J., Lovestone S. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 2007, 25:81-86.
74. Hotte M., Thuault S., Dineley K.T., Hemmings H.C., Nairn A.C., Jay T.M. Phosphorylation of CREB and DARPP-32 during late LTP at hippocampal to prefrontal cortex synapses in vivo. Synapse 2007, 61:24-28.
75. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr. Bull. 2009, 35:549-562.
76. Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., Woodgett J.R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. Embo J. 1993, 12:803-808.
77. Hyman S.E., Malenka R.C., Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu. Rev. Neurosci. 2006, 29:565-598.
78. Javanbakht A. Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia. Med. Hypotheses 2006, 67:1173-1184.
79. Jay T.M., Rocher C., Hotte M., Naudon L., Gurden H., Spedding M. Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases. Neurotox. Res. 2004, 6:233-244.
80. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
81. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets 2006, 7:1421-1434.
82. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007, 32:577-595.
83. Kalueff A.V., Ren-Patterson R.F., Murphy D.L. The developing use of heterozygous mutant mouse models in brain monoamine transporter research. Trends Pharmacol. Sci. 2007, 28:122-127.
84. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 2001, 52:503-517.
85. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
86. Kelley A.E. Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning. Neurosci. Biobehav. Rev. 2004, 27:765-776.
87. Kienast T., Heinz A. Dopamine and the diseased brain. CNS Neurol. Disord. Drug Targets 2006, 5:109-131.
88. Koros E., Dorner-Ciossek C. The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect. 2007, 20:437-445.
89. Kozlovsky N., Belmaker R.H., Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry 2000, 157:831-833.
90. Kozlovsky N., Belmaker R.H., Agam G. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur. Neuropsychopharmacol. 2002, 12:13-25.
91. Lai W.-S., Xu B., Westphal K.G.C., Paterlini M., Olivier B., Pavlidis P., Karayiorgou M., Gogos J.A. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16906-16911.
92. Laruelle M., Frankle W.G., Narendran R., Kegeles L.S., Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D2 receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 2005, 27:S16-S24.
93. Le Foll B., Diaz J., Sokoloff P. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci. 2005, 76:1281-1296.
94. Lee S.P., So C.H., Rashid A.J., Varghese G., Cheng R., Lanca A.J., O'Dowd B.F., George S.R. Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 2004, 279:35671-35678.
95. Lefkowitz R.J., Whalen E.J. beta-arrestins: traffic cops of cell signaling. Curr. Opin. Cell Biol. 2004, 16:162-168.
96. Lefkowitz R.J., Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 2005, 308:512-517.
97. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004, 29:1426-1431.
98. Li X., Rosborough K.M., Friedman A.B., Zhu W., Roth K.A. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol. 2007, 10:7-19.
99. Li Y.C., Xi D., Roman J., Huang Y.Q., Gao W.J. Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J. Neurosci. 2009, 29:15551-15563.
100. Lovestone S., Killick R., Di Forti M., Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007, 30:142-149.
101. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. Embo J. 2001, 20:27-39.
102. Maguire G.A. Comprehensive understanding of schizophrenia and its treatment. Am. J. Health Syst. Pharm. 2002, 59:S4-11.
103. Masri B., Salahpour A., Didriksen M., Ghisi V., Beaulieu J.-M., Gainetdinov R.R., Caron M.G. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13656-13661.
104. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1159-1172.
105. Miller J.S., Tallarida R.J., Unterwald E.M. Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology 2009, 56:1116-1123.
106. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
107. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10:79-104.
108. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
109. Molteni R., Calabrese F., Racagni G., Fumagalli F., Riva M.A. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol. Ther. 2009, 124:74-85.
110. Moore C.A., Milano S.K., Benovic J.L. Regulation of receptor trafficking by GRKs and arrestins. Annu. Rev. Physiol. 2007, 69:451-482.
111. Morice E., Denis C., Macario A., Giros B., Nosten-Bertrand M. Constitutive hyperdopaminergia is functionally associated with reduced behavioral lateralization. Neuropsychopharmacology 2005, 30:575-581.
112. Morice E., Billard J.M., Denis C., Mathieu F., Betancur C., Epelbaum J., Giros B., Nosten-Bertrand M. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology 2007, 32:2108-2116.
113. Morice E., Denis C., Giros B., Nosten-Bertrand M. Evidence of long-term expression of behavioral sensitization to both cocaine and ethanol in dopamine transporter knockout mice. Psychopharmacology 2009, (Berl).
114. Morrow B.A., Elsworth J.D., Lee E.J., Roth R.H. Divergent effects of putative anxiolytics on stress-induced fos expression in the mesoprefrontal system of the rat. Synapse 2000, 36:143-154.
115. Nadri C., Dean B., Scarr E., Agam G. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res. 2004, 71:377-382.
116. Neve K.A., Seamans J.K., Trantham-Davidson H. Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 2004, 24:165-205.
117. Nicola S.M., Surmeier J., Malenka R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu. Rev. Neurosci. 2000, 23:185-215.
118. Palmiter R.D. Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice. Ann. N. Y. Acad. Sci. 2008, 1129:35-46.
119. Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L., Lu J., Lo E., Wu D., Saule E., Bouschet T., Matthews P., Isaac J.T.R., Bortolotto Z.A., Wang Y.T., Collingridge G.L. LTP inhibits LTD in the hippocampus via regulation of GSK3[beta]. Neuron 2007, 53:703-717.
120. Peineau S., Bradley C., Taghibiglou C., Doherty A., Bortolotto Z.A., Wang Y.T., Collingridge G.L. The role of GSK-3 in synaptic plasticity. Br. J. Pharmacol. 2008, 153:S428-S437.
121. Peineau S., Nicolas C.S., Bortolotto Z.A., Bhat R.V., Ryves W.J., Harwood A.J., Dournaud P., Fitzjohn S.M., Collingridge G.L. A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases. Mol. Brain 2009, 2:22.
122. Perrine S.A., Miller J.S., Unterwald E.M. Cocaine regulates protein kinase B and glycogen synthase kinase-3 activity in selective regions of rat brain. J. Neurochem. 2008, 107:570-577.
123. Premont R.T., Gainetdinov R.R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 2007, 69:511-534.
124. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van Craenendonck H., Goris I., Daneels G., Bouwknecht J.A., Steckler T. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J. Neurosci. 2006, 26:9022-9029.
125. Rashid A.J., So C.H., Kong M.M.C., Furtak T., El-Ghundi M., Cheng R., O'Dowd B.F., George S.R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:654-659.
126. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 2009, 156:885-898.
127. Reynolds G.P. Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective. Expert Opin. Pharmacother. 2001, 2:543-548.
128. Robinson S., Sotak B.N., During M.J., Palmiter R.D. Local dopamine production in the dorsal striatum restores goal-directed behavior in dopamine-deficient mice. Behav. Neurosci. 2006, 120:196-200.
129. Robinson S., Rainwater A.J., Hnasko T.S., Palmiter R.D. Viral restoration of dopamine signaling to the dorsal striatum restores instrumental conditioning to dopamine-deficient mice. Psychopharmacology (Berl) 2007, 191:567-578.
130. Robinson T.E., Jurson P.A., Bennett J.A., Bentgen K.M. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res. 1988, 462:211-222.
131. Robinson T.E., Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J. Neurosci. 1997, 17:8491-8497.
132. Rodriguiz R.M., Chu R., Caron M.G., Wetsel W.C. Aberrant responses in social interaction of dopamine transporter knockout mice. Behav. Brain Res. 2004, 148:185-198.
133. Roh M.S., Seo M.S., Kim Y., Kim S.H., Jeon W.J., Ahn Y.M., Kang U.G., Juhnn Y.S., Kim Y.S. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp. Mol. Med. 2007, 39:353-360.
134. Scheid M.P., Woodgett J.R. PKB/AKT: functional insights from genetic models. Nat. Rev. Mol. Cell. Biol. 2001, 2:760-768.
135. Schloesser R.J., Huang J., Klein P.S., Manji H.K. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008, 33:110-133.
136. Seamans J.K., Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 2004, 74:1-58.
137. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 2002, 47:27-38.
138. Seeman P., Weinshenker D., Quirion R., Srivastava L.K., Bhardwaj S.K., Grandy D.K., Premont R.T., Sotnikova T.D., Boksa P., El-Ghundi M., O'Dowd B.F., George S.R., Perreault M.L., Mannisto P.T., Robinson S., Palmiter R.D., Tallerico T. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:3513-3518.
139. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., Roder J.C., Quirion R., Boksa P., Srivastava L.K., Yanai K., Weinshenker D., Sumiyoshi T. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006, 60:319-346.
140. Senior S.L., Ninkina N., Deacon R., Bannerman D., Buchman V.L., Cragg S.J., Wade-Martins R. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur. J. Neurosci. 2008, 27:947-957.
141. Sereno L., Coma M., Rodriguez M., Sanchez-Ferrer P., Sanchez M.B., Gich I., Agullo J.M., Perez M., Avila J., Guardia-Laguarta C., Clarimon J., Lleo A., Gomez-Isla T. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 2009, 35:359-367.
142. Sesack S.R., Grace A.A. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010, 35:27-47.
143. Sharp F.R., Tomitaka M., Bernaudin M., Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci. 2001, 24:330-334.
144. Simpson E.H., Kellendonk C., Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010, 65:585-596.
145. Spielewoy C., Gonon F., Roubert C., Fauchey V., Jaber M., Caron M.G., Roques B.P., Hamon M., Betancur C., Maldonado R., Giros B. Increased rewarding properties of morphine in dopamine-transporter knockout mice. Eur. J. Neurosci. 2000, 12:1827-1837.
146. Spielewoy C., Roubert C., Hamon M., Nosten-Bertrand M., Betancur C., Giros B. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav. Pharmacol. 2000, 11:279-290.
147. Spittaels K., Van den Haute C., Van Dorpe J., Terwel D., Vandezande K., Lasrado R., Bruynseels K., Irizarry M., Verhoye M., Van Lint J., Vandenheede J.R., Ashton D., Mercken M., Loos R., Hyman B., Van der Linden A., Geerts H., Van Leuven F. Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice. Neuroscience 2002, 113:797-808.
148. Sutton L.P., Honardoust D., Mouyal J., Rajakumar N., Rushlow W.J. Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J. Neurochem. 2007, 102:153-169.
149. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science 2003, 302:1412-1415.
150. Svenningsson P., Nishi A., Fisone G., Girault J.-A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004, 44:269-296.
151. Tan C.M., Brady A.E., Nickols H.H., Wang Q., Limbird L.E. Membrane trafficking of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2004, 44:559-609.
152. Tan H.Y., Nicodemus K.K., Chen Q., Li Z., Brooke J.K., Honea R., Kolachana B.S., Straub R.E., Meyer-Lindenberg A., Sei Y., Mattay V.S., Callicott J.H., Weinberger D.R. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J. Clin. Invest. 2008, 118:2200-2208.
153. Tenn C.C., Fletcher P.J., Kapur S. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr. Res. 2003, 64:103-114.
154. Tzavara E.T., Li D.L., Moutsimilli L., Bisogno T., Di Marzo V., Phebus L.A., Nomikos G.G., Giros B. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 2006, 59:508-515.
155. Vacher C.M., Gassmann M., Desrayaud S., Challet E., Bradaia A., Hoyer D., Waldmeier P., Kaupmann K., Pevet P., Bettler B. Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice. J. Neurochem. 2006, 97:979-991.
156. Valjent E., Corvol J.C., Pages C., Besson M.J., Maldonado R., Caboche J. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J. Neurosci. 2000, 20:8701-8709.
157. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., Greengard P., Herve D., Girault J.A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:491-496.
158. Valjent E., Corvol J.C., Trzaskos J.M., Girault J.A., Herve D. Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci. 2006, 7:20.
159. Wiedholz L.M., Owens W.A., Horton R.E., Feyder M., Karlsson R.M., Hefner K., Sprengel R., Celikel T., Daws L.C., Holmes A. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol. Psychiatry 2008, 13:631-640.
160. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376:572-575.
161. Woodgett J.R. Judging a protein by more than its name: GSK-3. Sci. STKE 2001, (re12-).
162. Xu T.-X., Sotnikova T.D., Liang C., Zhang J., Jung J.U., Spealman R.D., Gainetdinov R.R., Yao W.-D. Hyperdopaminergic tone erodes prefrontal long-term potential via a D2 receptor-operated protein phosphatase gate. J. Neurosci. 2009, 29:14086-14099.
163. Yao W.D., Gainetdinov R.R., Arbuckle M.I., Sotnikova T.D., Cyr M., Beaulieu J.M., Torres G.E., Grant S.G., Caron M.G. Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 2004, 41:625-638.
164. Yee B.K., Keist R., von Boehmer L., Studer R., Benke D., Hagenbuch N., Dong Y., Malenka R.C., Fritschy J.-M., Bluethmann H., Feldon J., Mohler H., Rudolph U. A schizophrenia-related sensorimotor deficit links alpha3-containing GABAA receptors to a dopamine hyperfunction. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17154-17159.
165. Zhu L.-Q., Wang S.-H., Liu D., Yin Y.-Y., Tian Q., Wang X.-C., Wang Q., Chen J.-G., Wang J.-Z. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J. Neurosci. 2007, 27:12211-12220.
166. Zhu L.Q., Liu D., Hu J., Cheng J., Wang S.H., Wang Q., Wang F., Chen J.G., Wang J.Z. GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. J. Neurosci. 2010, 30:3624-3633.
167. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1982-1987.
168. Zweifel L.S., Argilli E., Bonci A., Palmiter R.D. Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors. Neuron 2008, 59:486-496.
169. Zweifel L.S., Parker J.G., Lobb C.J., Rainwater A., Wall V.Z., Fadok J.P., Darvas M., Kim M.J., Mizumori S.J.Y., Paladini C.A., Phillips P.E.M., Palmiter R.D. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7281-7288.